Does PEMBROLIZUMAB Cause Interstitial lung disease? 2,113 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 2,113 reports of Interstitial lung disease have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 2.5% of all adverse event reports for PEMBROLIZUMAB.
2,113
Reports of Interstitial lung disease with PEMBROLIZUMAB
2.5%
of all PEMBROLIZUMAB reports
869
Deaths
1,276
Hospitalizations
How Dangerous Is Interstitial lung disease From PEMBROLIZUMAB?
Of the 2,113 reports, 869 (41.1%) resulted in death, 1,276 (60.4%) required hospitalization, and 292 (13.8%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for PEMBROLIZUMAB.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
TOCILIZUMAB (1,229)
Which PEMBROLIZUMAB Alternatives Have Lower Interstitial lung disease Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G